When Hair Loss on Zepbound (Tirzepatide) Becomes a Reason to Stop

What the Zepbound label reports

The hair loss numbers come from a pool of two placebo-controlled trials, Study 1 (SURMOUNT-1) and Study 2 (SURMOUNT-2), in adults with obesity or overweight, with or without type 2 diabetes, treated for up to 72 weeks plus a 4-week off-drug follow-up [1]. That safety population was 958 patients on placebo, 630 on 5 mg, 948 on 10 mg and 941 on 15 mg [1].

In that pool, hair loss was reported by 1% of placebo patients and by 5% of the 5 mg group, 4% of the 10 mg group and 5% of the 15 mg group [1]. The rates do not climb steadily with dose. The label describes hair loss as associated with weight reduction and more frequent in women: 7.1% of women versus 0.5% of men on Zepbound, against 1.3% of women and 0% of men on placebo [1].

Hair loss appears in the label's list of adverse reactions reported in at least 5% of Zepbound-treated patients [1]. And no Zepbound-treated patient discontinued treatment because of it, while one placebo-treated patient did [1].

Is hair loss a listed reason to stop Zepbound?

No. Hair loss is a listed adverse reaction of Zepbound, but the label gives no instruction to stop for it [1]. Other parts of the label do direct discontinuation for specific events: it says to discontinue Zepbound if pancreatitis is suspected, to seek medical attention promptly and discontinue if a serious hypersensitivity reaction is suspected, and to discontinue when pregnancy is recognized [1].

For scale, discontinuation for any adverse reaction in the pooled trials was 4.8% on 5 mg, 6.3% on 10 mg and 6.7% on 15 mg, versus 3.4% on placebo, and the majority of those who stopped did so in the first few months because of gastrointestinal reactions [1].

What is known about why it happens

The label associates hair loss with weight reduction and describes no effect of tirzepatide on hair follicles [1]. A 2026 systematic review screened 133 studies and included 24. It found androgenetic alopecia and telogen effluvium to be the predominant subtypes reported with GLP-1 receptor agonists, with telogen effluvium most often linked to tirzepatide, the agent the review associates with the greatest magnitude of weight loss. Rapid weight loss came up as a potential contributor, and women appeared disproportionately affected. The authors concluded that causality still has to be established [5].

What other hair-loss studies found

Other studies have looked at who reports hair loss with GLP-1 receptor agonists and how often. A cross-sectional questionnaire study of 254 people using GLP-1 receptor agonists for weight loss in Saudi Arabia, run from January to June 2025, found severe hair loss significantly more common among Mounjaro users (43.4%) and Saxenda users (42.9%) than other groups (P<0.001), and men were less likely than women to report hair loss (adjusted odds ratio 0.36) [6].

A separate retrospective review of FDA Adverse Event Reporting System entries found alopecia among the five most common skin reactions reported with GLP-1 receptor agonists, and found significantly higher reported rates of alopecia when the drugs were used for type 2 diabetes than for weight management (P=0.000) [7]. Reporting-database findings like these reflect spontaneous reports rather than comparative clinical risk or causality [3].

What stopping costs in weight terms

Stopping tirzepatide was followed by weight regain in SURMOUNT-4. In that trial, 783 adults received open-label tirzepatide at the maximum tolerated dose (10 or 15 mg) for 36 weeks, and 670 of them were then randomized to continue tirzepatide or switch to placebo for 52 more weeks. Those 670 had lost a mean 20.9% of body weight by week 36. From week 36 to week 88, weight changed by -5.5% in those who continued and by +14.0% in those switched to placebo, a difference of 19.4 percentage points [4].

Switching to semaglutide instead

In the 2026 systematic review, semaglutide and tirzepatide had the highest reported hair-loss rates among GLP-1 drugs [5]. Analyses of the FDA Adverse Event Reporting System have reached different results on the two. One analysis of reports from mid-2022 to mid-2025 found a positive reporting association with alopecia for semaglutide (adjusted reporting odds ratio 1.23, 95% CI 1.11 to 1.35) and lower or non-significant signals for tirzepatide [2]. Another, covering reports from January 2022 through June 2026, found alopecia relatively more frequently reported with tirzepatide [3]. Neither measures comparative risk in patients [3].

For weight, SURMOUNT-5 randomized 751 adults with obesity and no type 2 diabetes to maximum tolerated tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) for 72 weeks; weight fell 20.2% with tirzepatide and 13.7% with semaglutide [8].